Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™

Top Players Covered in the Antidepressants Market Research Report Are Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), AstraZeneca (Cambridge,… Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™ Top Players Covered in the Antidepressants Market Research Report Are Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), AstraZeneca (Cambridge,...

READ MORE Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™

SPRAVATO®▼ (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has authorised the expanded use of SPR SPRAVATO ® ▼ (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder This milestone makes esketamine nasal spray the first N-methyl-D-aspartate (NMDA) antagonist to...

READ MORE SPRAVATO®▼ (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the… Click to Tweet : #BREAKINGNEWS: FDA approves a new indication for @JanssenUS medicine for depressive symptom improvement in adults with major depression and suicidal behavior. Read full announcement here: https://ctt.ec/7yfjG+ Depression is the leading cause of disability...

READ MORE Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

New Hope for Depression on the Horizon

The FDA accepts a New Drug Application for novel antidepressant. Unlike other available antidepressants, it is believed the SNDRI class of medications will be relatively beneficial in preserving patients’ sexual functions . Data also suggests SNDRIs will have a better safety profile, produce a more rapid onset, and provide better efficacy . 1 SNDRIs fall under the category of triple...

READ MORE New Hope for Depression on the Horizon

Generated by Feedzy